Saturday 17 October 2026 Export ICLR’s income statement to Excel — free account

ICON PLC

ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024. In the quarter to June 2026, revenue grew 1.20%, EPS fell 59.3%, free cash flow grew 109.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

170.18 4.95 −2.83%

Follow ICLR

Alert me

Market cap: $13.5B
P/E: 254×
Fwd P/E: 23.8×
Dividend yield: —
F-score: 6/9
Altman Z: 2.01
Beneish M: −2.62
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 4.04

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	9	3	—

Insider Ownership 0.65%

Capital & Financial Ratios $m

Market Cap 13,510.00

Revenue 8,294.42

Net Income 42.34

Free Cash Flow 883.82

Net Debt 2,462.16

Current Ratio 0.95

Debt/Equity 0.36

P/E ratio 254.23

Fwd P/E 23.80

P/S ratio 1.58

P/B ratio 1.39

Past 5Y EPS Growth (13.96%)

This Y EPS Growth (15.53%)

Next Y EPS Growth 11.90%

Next Y revenue growth (1.36%)

Next 5Y EPS Growth 2.02%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 99.30%

10-year low 10-year high

P/S against its own 10 years 9.10%

10-year low 10-year high

P/B against its own 10 years 9.62%

10-year low 10-year high

EV/Sales against its own 10 years 8.33%

10-year low 10-year high

EV/FCF against its own 10 years 17.91%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	380	539	647	928
Receivables	1,947	1,556	1,652	1,651
Inventory	—	—	—	—
Other	952	1,040	1,097	1,054
	3,411	3,275	3,502	3,749

	2023	2024	2025	Q'26
Payables	132	173	192	118
ST’ Debt	110	30	530	1,280
Other	915	910	905	917
	2,826	2,635	3,196	3,935

Compound Annual Growth %

	10y	5y	3y
Sales	18.01%	24.15%	2.15%
Cash Flow	14.02%	12.78%	22.53%
Earnings	(0.43%)	(7.15%)	(23.15%)
Book Value	28.26%	37.80%	2.66%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2,034	2,063	—	—	—
’25	2,015	2,039	2,043	2,154	8,251
’24	2,090	2,120	2,030	1,948	8,189
’23	1,979	2,020	2,055	2,066	8,120
’22	1,902	1,935	1,942	1,962	7,741
’21	858	871	1,866	1,885	5,481
’20	715	620	702	760	2,797

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	167	281	—	—	—
’25	268	146	388	234	1,036
’24	327	219	403	338	1,287
’23	176	204	342	440	1,161
’22	227	182	214	(59)	563
’21	112	128	299	290	829
’20	143	118	112	195	568

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	136	239	—	—	—
’25	239	114	334	175	862
’24	300	182	359	277	1,119
’23	149	172	312	387	1,020
’22	207	154	176	(116)	421
’21	103	115	275	242	735
’20	131	108	105	183	527

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.36	0.94	—	—	—
’25	1.90	2.30	0.03	(1.67)	2.90
’24	2.25	1.76	2.36	2.53	9.53
’23	1.41	1.40	1.97	2.60	7.40
’22	1.36	1.41	1.94	1.42	6.13
’21	1.82	1.38	(1.17)	0.92	2.25
’20	1.62	0.90	1.72	1.90	6.15

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	62.31	74.30	101.22	118.10	104.28	168.76	171.43	181.92	183.38	125.10	Analyst estimates 2026–2028 Powerpack
	High	85.74	124.48	155.33	172.45	215.29	313.00	312.28	288.50	347.72	228.29
People
People	Employees	12,500	13,250	13,670	14,650	15,730	38,330	41,100	41,100	41,900	40,100
	Revenue/emp, $m	0.13	0.13	0.19	0.19	0.18	0.14	0.19	0.20	0.20	0.21
Income, $m
Income, $m	Revenue	1,666	1,758	2,596	2,806	2,797	5,481	7,741	8,120	8,189	8,251
	Gross margin, %	42.31	41.58	29.95	29.64	29.22	27.52	28.60	29.56	28.95	26.37
	EBT	300	328	365	427	381	197	568	624	804	252
	EBT margin, %	18.01	18.66	14.05	15.22	13.63	3.59	7.34	7.69	9.82	3.06
	Net income	262	281	323	376	333	153	505	612	739	229
	Depreciation	60	61	66	92	66	315	570	586	489	383
Per share, $
Per share, $	Revenue	30.16	32.49	47.96	52.10	52.92	81.67	94.95	98.90	99.28	105.21
	Earnings	4.87	5.20	6.17	6.85	6.20	2.28	6.20	7.46	9.60	2.92
	Cash flow	4.69	7.08	4.96	7.66	10.75	12.36	6.91	14.14	15.60	13.21
	Capex	(0.77)	(0.83)	(0.89)	(0.94)	(0.77)	(1.40)	(1.74)	(1.71)	(2.04)	(2.22)
	Free cash flow	3.92	6.25	4.07	6.72	9.97	10.96	5.17	12.43	13.56	10.99
	Book value	17.11	22.00	25.02	30.78	35.00	120.20	104.23	112.55	114.46	117.23
	Shares, m	55	54	54	54	53	67	82	82	82	78
Valuation, ×
Valuation, ×	P/E	15.53	22.06	21.68	25.14	31.45	102.89	31.27	37.64	23.39	70.64
	P/S	2.48	3.52	2.69	3.31	3.68	3.79	2.04	2.84	2.11	1.73
	P/B	4.37	5.20	5.16	5.60	5.57	2.58	1.86	2.49	1.83	1.55
	EV/Sales	2.74	3.72	2.79	3.26	3.52	4.65	2.60	3.26	2.46	2.07
	EV/FCF	21.08	19.31	32.86	25.24	18.66	34.63	47.84	25.92	18.04	19.77
Cash, $m
Cash, $m	Operating cash flow	259	383	269	413	568	829	563	1,161	1,287	1,036
	Capex	(43)	(45)	(48)	(51)	(41)	(94)	(142)	(141)	(168)	(174)
	Free cash flow	217	338	220	362	527	735	421	1,020	1,119	862
Balance, $m
Balance, $m	Working capital	464	535	720	494	979	462	538	586	640	306
	Total debt	349	349	349	427	372	5,436	4,654	3,776	3,426	3,402
	Net debt	88	(12)	(106)	(143)	(470)	4,682	4,364	3,396	2,887	2,755
	Shareholders’ equity	945	1,191	1,354	1,658	1,850	8,067	8,498	9,241	9,441	9,193
Returns, %
Returns, %	ROA	14.80	14.17	14.34	14.22	10.48	1.47	2.92	3.58	4.40	1.39
	ROIC	18.86	17.93	18.70	17.89	17.72	1.86	3.86	4.73	5.23	2.32
	ROE	30.70	26.35	25.35	24.83	18.95	3.09	6.10	6.90	7.91	2.46

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DGX Quest Diagnostics Incorporated	$26.4B	24.6×	20.8×	+10.21% (above 0%: growing)	+14.74% (above 0%: growing)	+5.28% (above 0%: growing)	33.75%	15.08%	Compare
LH Labcorp Holdings Inc.	$26.4B	26.2×	19.0×	+5.78% (above 0%: growing)	+28.42% (above 0%: growing)	−42.01% (below 0%: shrinking)	29.80%	12.10%	Compare
GH Guardant Health, Inc.	$22.3B	— (loss-making)	— (loss-making)	+44.33% (above 0%: growing)	n/m	−5.46% (below 0%: shrinking)	65.39%	(38.55%)	Compare
MEDP Medpace Holdings, Inc.	$17.6B	35.6×	26.7×	+17.24% (above 0%: growing)	+36.39% (above 0%: growing)	−3.03% (below 0%: shrinking)	71.36%	20.76%	Compare
RVTY Revvity Inc.	$17.3B	72.7×	37.5×	+1.31% (above 0%: growing)	+2.17% (above 0%: growing)	+59.29% (above 0%: growing)	57.13%	12.24%	Compare
CRL Charles River Laboratories International, Inc.	$14.6B	— (loss-making)	29.6×	−2.72% (below 0%: shrinking)	n/m	−12.22% (below 0%: shrinking)	36.19%	11.94%	Compare
ICLR ICON PLC	$13.5B	254×	23.8×	+1.20% (above 0%: growing)	−59.31% (below 0%: shrinking)	+109.66% (above 0%: growing)	23.23%	6.68%
QGEN QIAGEN N.V.	$9.5B	23.6×	17.5×	+0.28% (above 0%: growing)	+7.94% (above 0%: growing)	+30.45% (above 0%: growing)	63.62%	24.75%	Compare
TWST Twist Bioscience Corporation	$9.5B	— (loss-making)	— (loss-making)	+23.24% (above 0%: growing)	n/m	−7.23% (below 0%: shrinking)	52.76%	(30.65%)	Compare
Median of peers	$17.4B	26.2×	23.8×	+8.00%	+14.74%	−4.24%	54.95%	12.17%

All 52 Diagnostics & Research stocks →

ICON PLC (ICLR) key facts

Strength: ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
ICON PLC (ICLR) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ICLR traded at $170.18, a market capitalization of $13.5 billion.
Return on equity was 2.46% and debt-to-equity 0.36.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 2.01 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.